Safety and compliance of capecitabine and temozolomide in patients with advanced neuroendocrine tumours.

Georgios Papaxoinin, Lynne McCallum, Magdy Nasralla, Richard Hubner, Mairead Mcnamara, Juan Valle, Wasat Mansoor

Research output: Contribution to conferenceAbstractpeer-review

Abstract

Introduction: Limited treatment options exist for patients (pts) with advancedpulmonary carcinoids (PC). Capecitabine-temozolomide (CAPTEM) hasdemonstrated significant efficacy in pts with pancreatic neuroendocrinetumours. However, its role in PC remains unexplored. Aim(s): The aim of thisstudy was to examine the efficacy of CAPTEM in advanced PC. Materials andmethods: Pts were treated with capecitabine 750mg/m2 BD day1-14 andtemozolomide 200mg/m2 OD day10-14 of a 4-week cycle up to maximum of 6cycles. All pts were treated at the Christie NHS Hospital from 3/2014 to11/2015. Results: 19 pts were included; 8 (42%) had typical and 11 (58%)atypical PC. Fourteen pts (74%) had ECOG performance status (PS) 0-1 and5 (26%) PS 2. The number of involved organs was 1/2 in 8 pts (42%) and >2 in11 (58%). The most frequent site of metastasis was the liver. Prior treatmentsincluded octreotide (10 pts, 53%), pasireotide (2 pts, 11%), chemotherapy (5pts, 26%), interferon (2 pts, 11%) and everolimus (1pt, 5%). Five pts (26%)received CAPTEM as first line treatment and 8 (42%) as second line. Mediannumber of cycles was 4. Seven pts (37%) completed 6 cycles. Among 17assessable pts, 2 (12%) had partial response, 9 (53%) stable disease and 6(35%) disease progression. After 8 months median follow-up, 11 ptsprogressed and 6 died. Median progression-free survival was 5 and overallsurvival 10 months. Conclusion: CAPTEM has moderate activity in PC.Predictive factors of efficacy could not be identified. Keywords: pulmonarycarcinoids, capecitabine, temozolomide
Original languageEnglish
Pages71-71
Number of pages1
Publication statusPublished - Mar 2016
Event13th Annual ENETS Conference for the Diagnosis and Treatment of Neuroendocrine Tumor Disease - Barcelona, Spain
Duration: 9 Mar 201611 Mar 2016

Conference

Conference13th Annual ENETS Conference for the Diagnosis and Treatment of Neuroendocrine Tumor Disease
Country/TerritorySpain
CityBarcelona
Period9/03/1611/03/16

Research Beacons, Institutes and Platforms

  • Manchester Cancer Research Centre

Fingerprint

Dive into the research topics of 'Safety and compliance of capecitabine and temozolomide in patients with advanced neuroendocrine tumours.'. Together they form a unique fingerprint.

Cite this